P

Inventor

HABER LAURIC

US20 patents
⚠️ This page may combine multiple inventors who share the name “HABER LAURIC”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

REGENERON PHARMA

18 patents
US10772972B2Sep 15, 2020

Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof

REGENERON PHARMA44 citations97
US10738130B2Aug 11, 2020

Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof

REGENERON PHARMA50 citations97
US10179819B2Jan 15, 2019

Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

REGENERON PHARMA25 citations93
US11155633B2Oct 26, 2021

Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

REGENERON PHARMA9 citations85
US11548947B2Jan 10, 2023

Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof

REGENERON PHARMA10 citations84
US11453721B2Sep 27, 2022

Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof

REGENERON PHARMA10 citations84
US11485793B2Nov 1, 2022

Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof

REGENERON PHARMA4 citations83
US10941208B2Mar 9, 2021

Anti-MUC16 antibodies

REGENERON PHARMA6 citations83
US12077603B2Sep 3, 2024

Multispecific antigen-binding molecules for cell targeting and uses thereof

REGENERON PHARMA3 citations72
US12065508B2Aug 20, 2024

Multispecific antigen-binding molecules for cell targeting and uses thereof

REGENERON PHARMA3 citations72
US11952430B2Apr 9, 2024

Multispecific antigen-binding molecules for cell targeting and uses thereof

REGENERON PHARMA3 citations72
US11633501B2Apr 25, 2023

Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof

REGENERON PHARMA3 citations72
US12577304B2Mar 17, 2026

Anti-CD3 antibodies with low binding affinity

REGENERON PHARMA0 citations62
US12415856B2Sep 16, 2025

EGFR x CD28 multispecific antibodies

REGENERON PHARMA0 citations62
US12344677B2Jul 1, 2025

Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

REGENERON PHARMA0 citations62
US11912767B2Feb 27, 2024

EGFR × CD28 multispecific antibodies

REGENERON PHARMA1 citations62
US12570764B2Mar 10, 2026

Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof

REGENERON PHARMA0 citations61
US12441800B2Oct 14, 2025

Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof

REGENERON PHARMA0 citations61

GENENTECH INC

1 patent

FUH GERMAINE

1 patent